# Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

> **NCT02002936** · PHASE1 · COMPLETED · sponsor: **SymBio Pharmaceuticals** · enrollment: 1 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** SyB C-1101

## Key facts

- **NCT ID:** NCT02002936
- **Lead sponsor:** SymBio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02002936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02002936, "Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02002936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*